Bio­gen to pay $1.25B to de-risk a Tec­fidera patent bat­tle, and For­ward Phar­ma’s shares rock­et up

Bio­gen will pay For­ward Phar­ma $1.25 bil­lion in cash to help sat­is­fy the Dan­ish biotech’s claims that its flag­ship mul­ti­ple scle­ro­sis drug Tec­fidera in­ter­fered with its patents.

The pricey set­tle­ment comes in ex­change for a li­cense agree­ment on the tech­nol­o­gy used in the 480 mg dai­ly dose, which was at the cen­ter of the IP dis­pute. And if For­ward wins their in­ter­fer­ence case be­fore the Patent Tri­al and Ap­peal Board, Bio­gen has agreed to pay a roy­al­ty on sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.